Ptc Therapeutics Inc. | Mid-cap | Healthcare
$50.82
-1.78%
| Ptc Therapeutics Stock Comparison:
Ptc Therapeutics vs VertexPtc Therapeutics vs RegeneronPtc Therapeutics vs BridgeBio PharmaPtc Therapeutics vs Blueprint MedicinesPtc Therapeutics vs Bio-TechnePtc Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 1.2B
Gross Profit 1.2B 98.91%
Operating Income 969.5M 82.43%
Net Income 866.6M 73.68%
EPS (Diluted) $10.04

Balance Sheet Metrics

Total Assets 2.7B
Total Liabilities 2.8B
Shareholders Equity -185.8M

Cash Flow Metrics

Operating Cash Flow 866.3M
Free Cash Flow 867.6M

Revenue & Profitability Trend

Ptc Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i806.8M937.8M698.8M538.6M380.8M
Cost of Goods Sold i57.4M65.5M44.7M32.3M18.9M
Gross Profit i749.4M872.3M654.1M506.3M361.8M
Gross Margin % i92.9%93.0%93.6%94.0%95.0%
Operating Expenses
Research & Development i534.5M666.6M651.5M540.7M477.6M
Selling, General & Administrative i300.9M332.5M326.0M285.8M245.2M
Other Operating Expenses i-----
Total Operating Expenses i835.4M999.1M977.5M826.5M722.8M
Operating Income i-146.7M-349.4M-439.9M-374.9M-397.9M
Operating Margin % i-18.2%-37.3%-63.0%-69.6%-104.5%
Non-Operating Items
Interest Income i-----
Interest Expense i167.0M129.2M90.9M86.0M56.4M
Other Non-Operating Income-49.4M-217.5M-56.7M-57.4M51.3M
Pre-tax Income i-363.1M-696.1M-587.5M-518.3M-402.9M
Income Tax i176.0K-69.5M-28.5M5.6M35.2M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-363.3M-626.6M-559.0M-523.9M-438.2M
Net Margin % i-45.0%-66.8%-80.0%-97.3%-115.1%
Key Metrics
EBITDA i35.4M-102.7M-360.3M-368.7M-269.2M
EPS (Basic) i$-4.73$-8.37$-7.79$-7.43$-6.64
EPS (Diluted) i$-4.73$-8.37$-7.79$-7.43$-6.64
Basic Shares Outstanding i7684505574838392717286347046639366027908
Diluted Shares Outstanding i7684505574838392717286347046639366027908

Income Statement Trend

Ptc Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i779.7M594.0M279.8M189.7M208.8M
Short-term Investments i360.0M282.7M130.9M583.7M894.8M
Accounts Receivable i158.6M160.8M155.6M110.5M69.9M
Inventory i23.2M30.6M21.8M15.9M18.7M
Other Current Assets44.1M150.5M105.7M54.7M-
Total Current Assets i1.4B1.2B693.8M954.4M1.2B
Non-Current Assets
Property, Plant & Equipment i56.7M91.9M102.4M77.4M84.4M
Goodwill i283.5M544.2M870.6M889.5M880.0M
Intangible Assets i118.8M379.5M705.9M724.8M715.3M
Long-term Investments-----
Other Non-Current Assets20.7M36.2M48.6M46.5M60.6M
Total Non-Current Assets i339.5M677.1M1.0B983.7M976.5M
Total Assets i1.7B1.9B1.7B1.9B2.2B
Liabilities
Current Liabilities
Accounts Payable i17.3M6.0M27.3M23.0M18.7M
Short-term Debt i271.2M210.3M84.5M219.1M8.7M
Current Portion of Long-term Debt-----
Other Current Liabilities--72.1M1.5M22.3M
Total Current Liabilities i581.0M603.1M406.2M509.3M277.3M
Non-Current Liabilities
Long-term Debt i2.2B2.0B1.4B1.1B411.7M
Deferred Tax Liabilities i055.9M102.8M137.1M136.7M
Other Non-Current Liabilities21.4M141.0K2.6M674.7M660.1M
Total Non-Current Liabilities i2.2B2.1B1.6B1.4B1.4B
Total Liabilities i2.8B2.7B2.1B1.9B1.7B
Equity
Common Stock i77.0K75.0K72.0K71.0K70.0K
Retained Earnings i-3.6B-3.3B-2.7B-2.1B-1.6B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-1.1B-818.6M-347.1M1.4M482.0M
Key Metrics
Total Debt i2.5B2.2B1.5B1.3B420.4M
Working Capital i784.6M615.5M287.5M445.0M954.4M

Balance Sheet Composition

Ptc Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-363.3M-626.6M-559.0M-523.9M-438.2M
Depreciation & Amortization i75.7M236.6M128.8M64.1M43.5M
Stock-Based Compensation i74.6M131.2M110.3M103.5M70.3M
Working Capital Changes i24.6M-12.6M-58.3M-53.9M-20.6M
Operating Cash Flow i-323.3M-423.0M-412.3M-346.8M-161.5M
Investing Activities
Capital Expenditures i21.6M-28.4M-32.0M-28.2M-17.8M
Acquisitions i-----
Investment Purchases i-667.4M-212.5M-75.6M-543.3M-1.4B
Investment Sales i607.7M156.4M518.2M847.8M944.1M
Investing Cash Flow i111.9M-84.6M410.6M276.3M-523.4M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i00300.0M00
Debt Repayment i-1.5M-301.4M-151.3M-2.2M-46.2M
Financing Cash Flow i222.1M616.4M146.9M-2.2M593.2M
Free Cash Flow i-181.9M-279.0M-509.1M-336.7M-250.0M
Net Change in Cash i10.8M108.9M145.2M-72.7M-91.6M

Cash Flow Trend

Ptc Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 6.44
Forward P/E -12.33
Price to Book -19.08
Price to Sales 2.04
PEG Ratio -12.33

Profitability Ratios

Profit Margin 35.65%
Operating Margin -19.49%
Return on Equity 33.08%
Return on Assets 23.81%

Financial Health

Current Ratio 3.62
Debt to Equity -13.37
Beta 0.54

Per Share Data

EPS (TTM) $7.05
Book Value per Share $-2.60
Revenue per Share $22.70

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ptct3.6B6.44-19.0833.08%35.65%-13.37
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.